Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare


Charles River Discovery




Silicon Biosystems   




  View All Sponsors 

Second Annual

Next Generation Pathology

New Perspective on Tissue: Converting Complexion into Action


Day 1 | Day 2 | Download Brochure | View TRICON Attendees

Pathology studies structural and functional mechanisms of disease, making it the cornerstone of medical science. An array of innovative technologies is rapidly transforming the field of pathology and tissue analysis. Alongside these technological advances, we are also witnessing an expansion in pathology applications, both in the pharmaceutical industry and in the clinic. The second annual Next Generation Pathology symposium is designed to bring together pathologists and tissue analysis specialists working in the industry as well as in healthcare settings. The program will present solutions and case studies for various tissue analysis applications and will feature a broad array of novel technologies. 

Monday, February 11

7:30 am Registration and Morning Coffee

8:25 Chairperson’s Opening Remarks
Michael Roehrl, M.D., Ph.D., Associate Professor of Pathology, University of Toronto


Next Generation Biospecimen Science 

8:30 Next Generation Biospecimen Sciences: Systems Pathology and Pushing the Frontier of Personalized Clinical Trials

Michael Roehrl, M.D., Ph.D., Associate Professor of Pathology, University of Toronto

9:00 Biospecimen Science: Quantitative Assessment of Pre-Analytic Variables

David L. Rimm, M.D., Ph.D., Professor, Pathology, Yale University

Companion diagnostic tests are critically dependent on tissue quality.Cold Ischemic time is amongst the most important variable.We will show data on the effects of this variable in the diagnostic setting and show data on analytes that are particularly sensitive to this issue.

9:30 Establishing a Specialist National Breast Cancer Biobank

Valerie Speirs, Ph.D., Associate Professor, Leeds Institute of Molecular Medicine, University of Leeds

Research institutions often face barriers in gaining access to this resource as collections typically have restrictive access policies or an over burdensome application process. We will describe the steps taken to overcome these issues in establishing the first national Breast Biobank in the UK.

10:00 Coffee Break with Exhibit and Poster Viewing

10:30 Enhancing Accuracy When Using DNA from Formalin Fixed Biopsies in Clinical Diagnostics

Alexander Dobrovic, M.D., Head, Molecular Pathology R&D, Pathology, Peter MacCallum Cancer Centre

To overcome the issue of sequence artifacts in FFPE DNA, we show that pre-treatment with Uracil DNA glycosylase dramatically reduces C>T:G>A sequence artifacts using high resolution melting and Sanger sequencing approaches.

CST_Cell Signaling Technology11:00 Multiplexing for CTC’s and Tissue Diagnostics: Using Antibody Engineering to Develop Sensitive and Specific ImmunoassayHerbert Haack, Ph.D., Head, Clinical Assay Development, Cell Signaling TechnologyThere is unmet need to identify the multitude of new targets with clinical utility. Multiplexed immuno-assays of high specificity and sensitivity could be part of the diagnostics solution. A lung cancer assay for ALK, ROS1 and MET based on antibody engineering will be described.

11:30 Q&A with Speakers

12:00 pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

Novel Biomarker Assays 

1:25 Chairperson’s Remarks
Laura J. Tafe, M.D., Assistant Director, Molecular Pathology; Assistant Professor, Department of Pathology, Dartmouth-Hitchcock Medical Center

1:30 Qualifying Ligand Binding Assays in Tissues—The Future of Proteomics or Impossible Dream?

Robert Dunstan, Distinguished Scientist, Investigative Histology, BiogenIdec

With sophisticated immunostainers, digitization, high throughput morphometric methods and the development of tissue based reference standards the reality of true quantitation of tissue changes is not far away.

2:00 microRNAs as Biomarkers in Solid Tumors: Potential Role in Diagnosis, Prognosis and Therapy

Laura J. Tafe, M.D., Assistant Director, Molecular Pathology; Assistant Professor, Department of Pathology, Dartmouth-Hitchcock Medical Center

With the rapid advances in targeted therapeutics, it is becoming more crucial to characterize molecular changes in cancers.Micro RNAs (miRNAs) are potential new biomarkers with respect to solid tumors.

Advanced Cell Diagnostic - small logo2:30 Ultrasensitive RNA in situ Hybridization for Tissue Diagnostics

Yuling Luo, Ph.D., Founder, President & CEO, Advanced Cell Diagnostics, Inc.

RNA biomarkers are traditionally analyzed by “grind-and-bind” assays such as RT-PCR, which loses critical cellular and tissue context for clinical interpretation. Recent advances in in situ RNA analysis capable of detecting single RNA molecules in routine clinical specimens may finally enable more advanced RNA-based tissue diagnostics.

3:00 Refreshment Break with Exhibit and Poster Viewing


Predictive Tests for Improved Patient Outcomes 

3:30 Gene Panels vs. Whole Exome Sequencing in Cancer Molecular Testing

Madhuri Hegde, Ph.D., FACMG, Associate Professor, Senior Director, Emory Genetics Laboratory, Department of Human Genetics, Emory University School of Medicine

4:00 Next Generation Sequencing and Cancer Diagnostics

Phil Stephens, Ph.D., Vice President, Cancer Genomics, Foundation Medicine

Foundation Medicine has developed FoundationOne™, a CLIA-certified, comprehensive cancer genomic test that analyzes routine clinical specimens for somatic alterations in 189 relevant cancer genes. Experience with the initial 1,000 consecutive patients will be presented.

4:30 KEYNOTE PRESENTATION: Clinical Cancer Genotyping – Snapshot

John Iafrate, M.D., Ph.D., Assistant Professor, Pathology, Harvard Medical School; Assistant Pathologist, Massachusetts General Hospital

The challenges and opportunities of implementing a broad genotyping assay in routine clinical management of cancer patients will be discussed. Snapshot was launched over 3 years ago at the Massachusetts General Hospital, with the goal of providing all cancer patients with a genetic fingerprint to guide therapeutic decisions. Lessons learned will be outlined, and a roadmap to effectively move testing forward into the Next Gen sequencing era.

5:00 Breakout Discussions

NextGen Biospecimen Science
Michael Roehrl, M.D., Ph.D., Associate Professor of Pathology, University of Toronto 

Tumor-Stromal Interactions from Pathology Point of ViewDavid Tarin, M.D., Ph.D., Professor of Pathology, Director, UCSD Comprehensive Cancer Center

Biomarker Assay DevelopmentRobert Dunstan, Distinguished Scientist, Investigative Histology, BiogenIdec 


6:00 Close of Day

Day 1 | Day 2 | Download Brochure